The Danish Medicines Agency can again receive electronic adverse reaction reports via E2B

23 November 2020

Please be informed that the gateway for SUSAR submission is now available again.

If You after 48 hours have submissions that are pending acknowledgements, please contact the Danish Medicines Agency on this e-mail.

The Danish Medicines Agency has not been able to receive electronic SUSARs via E2B (DKMAEUDRA) from Thursday 19 November due to the implementation of a new IT system. The implementation has now been completed and it is again possible to report.

Reporting to EudraVigilance (EVCTMPROD) has not been affected.